已收盤 12-24 16:00:00 美东时间
+0.160
+1.17%
Bain Capital Specialty Finance ( ($BCSF) ) just unveiled an update. On December...
12-23 06:26
今日重点评级关注:HC Wainwright & Co.:维持Pyxis Oncology"买入"评级,目标价从5美元升至7美元;Stifel:维持Oculis Holding"买入"评级,目标价从35美元升至40美元
12-22 15:05
Keefe, Bruyette & Woods analyst Paul Johnson upgrades Bain Capital Specialty (NYSE:BCSF) from Market Perform to Outperform and maintains the price target from $16 to $16.
12-19 19:48
今日重点评级关注:HC Wainwright & Co.:维持PDS Biotechnology"买入"评级,目标价从13美元升至15美元;HC Wainwright & Co.:维持PepGen Inc."买入"评级,目标价从18美元升至20美元
11-14 10:43
Keefe, Bruyette & Woods analyst Paul Johnson maintains Bain Capital Specialty (NYSE:BCSF) with a Market Perform and lowers the price target from $17 to $16.
11-13 20:06
今日重点评级关注:HC Wainwright & Co.:维持Artiva Biotherapeutics"买入"评级,目标价从12美元升至15美元;Canaccord Genuity:维持Viking Therapeutics"买入"评级,目标价从106美元升至107美元
11-13 09:58
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据BCSF 2025年第三季度业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **核心收益指标:** - 净投资收益(NII):每股0.45美元,年化账面价值收益率10.3%,超出常规季度股息7% - 每股收益(EPS):0.29美元,年化账面价值回报率6.6% - 每股净资产价值(NAV):17.40美元 **投资组合表现:** - 投资组合公允价值:25亿美元,覆盖195家公司,分布在31个行业 - 加权平均收益率:摊销成本11.1%,公允价值11.2% - 总投资收入:6,720万美元 - 净收入:1,870万美元 **资产负债状
11-12 12:24
Bain Capital Specialty Finance ( ($BCSF) ) has shared an announcement. On Novem...
11-11 07:05
Bain Capital Specialty Finance (BCSF) declares $0.42/share quarterly dividend, in line with previous. Forward yield 12.07% Payable Dec. 30; for shareholders of record Dec. 16; ex-div Dec. 16. The Boar...
11-11 06:37
Companies Reporting Before The Bell • CBAK Energy Tech (NASDAQ:CBAT) is likely ...
11-10 19:12